Functional activity of antisera to group B streptococcal conjugate vaccines measured with an opsonophagocytosis assay and HL-60 effector cells

被引:19
作者
Guttormsen, Hilde-Kari [1 ]
Liu, Yongdong [1 ]
Paoletti, Lawrence C. [1 ]
机构
[1] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp,Dept Med, Boston, MA 02115 USA
来源
HUMAN VACCINES | 2008年 / 4卷 / 05期
关键词
opsonophagocytosis assay; HL-60; cells; group B Streptococcus; glycoconjugate vaccines;
D O I
10.4161/hv.4.5.5988
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Conjugate vaccines against group B Streptococcus (GBS), which is a leading cause of bacterial disease among newborns and the elderly with underlying illnesses, have progressed from animal studies to phase I and 2 clinical trials in healthy adults. Due to the wide-spread use of antibiotics to treat at-risk deliveries, a phase 3 efficacy trial of a GBS vaccine to prevent neonatal disease in the United States is unlikely. A viable approach to assess a vaccine's efficacy is to use a surrogate of protection which in the case of GBS is the opsonizing activity of serum antibody. The opsonophagocytosis assay (OPA) measures the ability of serum antibody to opsonize GBS for killing by effector cells in the presence of complement. In this report we demonstrate that differentiated HL-60 cells can substitute for human peripheral blood leukocytes (hPMNLs) in the OPA. Antisera to GBS type la CPS and type III CPS conjugate vaccines opsonized homologous GBS for killing at effector cells to GBS ratios of 2-4:1 regardless of whether HL-60 or hPMNLs were used. These results represent the first important step in developing a standardized, high-throughput OPA that could be used to assess the functional activity of vaccine-Induced antibody and potentially serve as a surrogate of efficacy.
引用
收藏
页码:370 / 374
页数:5
相关论文
共 22 条
[1]  
[Anonymous], 2002, FED REGISTER, V67, P37988
[2]   Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib [J].
Baker, CJ ;
Paoletti, LC ;
Wessels, MR ;
Guttormsen, HK ;
Rench, MA ;
Hickman, ME ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) :142-150
[3]   Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine [J].
Baker, CJ ;
Rench, MA ;
McInnes, P .
VACCINE, 2003, 21 (24) :3468-3472
[4]   ANTIBODY TO GROUP B-STREPTOCOCCUS TYPE-III IN HUMAN-SERA MEASURED BY A MOUSE PROTECTION TEST [J].
BALTIMORE, RS ;
BAKER, CJ ;
KASPER, DL .
INFECTION AND IMMUNITY, 1981, 32 (01) :56-61
[5]   Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines [J].
Brigtsen, AK ;
Kasper, DL ;
Baker, CJ ;
Jennings, HJ ;
Guttormsen, HK .
JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (09) :1277-1284
[6]   Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies [J].
Burton, Robert L. ;
Nahm, Moon H. .
CLINICAL AND VACCINE IMMUNOLOGY, 2006, 13 (09) :1004-1009
[7]   Use of HL-60 cell line to measure opsonic capacity of pneumococcal antibodies [J].
Fleck, RA ;
Romero-Steiner, S ;
Nahm, MH .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2005, 12 (01) :19-27
[8]  
Fusco PC, 1997, ADV EXP MED BIOL, V418, P841
[9]   Quantitative determination of antibodies to type III group B streptococcal polysaccharide [J].
Guttormsen, HK ;
Baker, CJ ;
Edwards, MS ;
Paoletti, LC ;
Kasper, DL .
JOURNAL OF INFECTIOUS DISEASES, 1996, 173 (01) :142-150
[10]   Type III group B streptococcal polysaccharide induces antibodies that cross-react with Streptococcus pneumoniae type 14 [J].
Guttormsen, HK ;
Baker, CJ ;
Nahm, MH ;
Paoletti, LC ;
Zughaier, SM ;
Edwards, MS ;
Kasper, DL .
INFECTION AND IMMUNITY, 2002, 70 (04) :1724-1738